Bone loss from Wnt inhibition mitigated by concurrent alendronate therapy

Dysregulated Wnt signaling is associated with the pathogenesis of cancers, fibrosis, and vascular diseases. Inhibition of Wnt signaling has shown efficacy in various pre-clinical models of these disorders. One of the key challenges in developing targeted anti-cancer drugs is to balance efficacy with...

Descripción completa

Detalles Bibliográficos
Autores principales: Madan, Babita, McDonald, Mitchell J., Foxa, Gabrielle E., Diegel, Cassandra R., Williams, Bart O., Virshup, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968037/
https://www.ncbi.nlm.nih.gov/pubmed/29844946
http://dx.doi.org/10.1038/s41413-018-0017-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968037/
https://www.ncbi.nlm.nih.gov/pubmed/29844946
http://dx.doi.org/10.1038/s41413-018-0017-8

Ejemplares similares